EP0395328A2 — Penylpyrimidone derivates and their use as therapeutic agents
Assigned to Smith Kline and French Laboratories Ltd · Expires 1990-10-31 · 36y expired
What this patent protects
Compounds of the formula (1) : <CHEM> and pharmaceutically acceptable salts thereof are described wherein R<1> is C1-6alkyl, C2-6alkenyl, C3-5cycloalkylC1-6alkyl, phenylC1-6alkyl or C1-6alkyl substituted by 1 to 6 fluoro groups; and R<2> is C1-6alkyl, phenyl, hy…
USPTO Abstract
Compounds of the formula (1) : <CHEM> and pharmaceutically acceptable salts thereof are described wherein R<1> is C1-6alkyl, C2-6alkenyl, C3-5cycloalkylC1-6alkyl, phenylC1-6alkyl or C1-6alkyl substituted by 1 to 6 fluoro groups; and R<2> is C1-6alkyl, phenyl, hydroxy, C1-6alkoxy, halo, -NHCOR<3>, -NHCONHR<4>, 5-tetrazolyl, -CO2R<5>, cyano, -CONR<6>R<7>, or -NR<8>R<9> wherein R<3> to R<7> are independently hydrogen or C1-6alkyl and R<8> and R<9> are independently hydrogen or C1-6alkyl optionally substituted by hydroxy provided that the carbon atom adjacent to the nitrogen atom is not substituted by hydroxy. Processes for their preparation, pharmaceutical compositions comprising them and their use as medicaments are also described.
Drugs covered by this patent
- Otezla (APREMILAST) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.